Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

The company’s system is placed in the subclavian vein, a blood vessel that runs under the collar bone bringing deoxygenated ...

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

(RTTNews) - Glucotrack, Inc. (GCTK), a medical technology ... This milestone study, which aimed to evaluate the safety of the implant, use, and removal of the CBGM sensor lead, confirms the ...

Glucotrack calls its device, which has no external on-body component, a continuous blood glucose monitor (CBGM). The implant is around the length and thickness of three US nickels, with a total ...

Goode, PhD, President & Chief Executive Officer of Glucotrack ... or device related serious adverse events reported from implant through seven days post-removal of the CBGM sensor lead.

Goode, PhD, President & Chief Executive Officer of Glucotrack. “With these positive results ... with no procedure or device related serious adverse events reported from implant through seven days post ...